Low-Level Viremia ‘Blips’ in Very Early HIV Infection

	Tweet

Intermittent low-level viremia (LLV) can occur in the very early stages of primary HIV infection, before the ramp-up phase of HIV viremia, according to a new report.

The findings suggest a theoretical risk that infective plasma could bypass current screening methods, but such a risk would be small, contributing to an estimated 1 in 5 million cases, Dr. Michael P. Busch of Blood Centers of the Pacific in San Francisco and colleagues write.

“Pathogen reduction methods, already applied to the manufacture of plasma components and derivatives and in various stages of trials and development for other blood components, seem to offer the best chance to counter the small theoretic risk of HIV transmission during the very early period of the infection,” Dr. Busch and colleagues conclude in the June 1st issue of the Journal of Acquired Immune Deficiency Syndromes.

Dr. Busch and his team assembled 15 panels of serial samples from plasma donors who eventually developed HIV infection. In 6 of the 15 panels, LLV was identified in samples preceding the first sample with HIV-1 RNA levels above 100 copies/mL, and separated from that sample by at least one negative sample. The LLV tests occurred 9 to 25 days before the first 100 copies/mL sample appeared.

The researchers estimate that the “blips” represent an HIV plasma concentration of 1 to 10 copies/mL, well below the 1,500 copies/mL necessary for heterosexual transmission. It is conceivable, however, that plasma with this LLV could be infective if used for plasma or platelet transfusion, they note.

The finding “presumably reflects intermittent escape or leakage of small amounts of HIV from mucosal and lymphoid tissues near the entry site into the bloodstream or from rare circulating infected CD4+ cells,” Dr. Busch and his team write.

“This observation confirms the capacity for early spread and dissemination of HIV after mucosal penetration, a property that needs to be taken into account in vaccine development and in other strategies for prevention and early treatment.”

J Acquir Immune Defic Syndr 2005;39:133-137.

RELATED STORIES:
FDA Advisory Panel Approves Home HIV Test Kit   FDA Approves New In-Home HIV Test   Home HIV test advances   Survey Reveals Support for Over-the Counter HIV Testing   F.D.A. Panel Weighs Preventive Use of H.I.V. Drug   Stem Cell Therapy Shows Promise in Fight Against HIV   Progress against HIV thwarted by patients’ unmet needs   California to test pill for HIV prevention   Mechanism of HIV spread has potential for future drug therapy   Seeking HIV treatment clues in the neem tree   HIV Prevention Pill’s Value Varies by Target   Using AIDS drugs to prevent infection: a bargain?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]